Search

Purpose: Inactivating mutations in mitochondrial aldehyde dehydrogenase 2 (ALDH2) are highly prevalent. The most common variant allele, ALDH2*2 , is present in 40%-50% of East Asians, and causes acetaldehyde accumulation, flushing and tachycardia after alcohol intake. The relationship between alcohol intake and ALDH2 genotype on semen parameters remains unknown., Materials and Methods: We conducted a cross-sectional study to determine the association between ALDH2 genotype, alcohol consumption and semen parameters among East Asian men. Volunteers completed a survey and submitted a semen sample for analysis. Participants were genotyped to determine ALDH2 status ( ALDH2*1/*1 , ALDH2*1/*2 , ALDH2*2/*2 ), and immunohistochemical staining was used to determine protein expression of ALDH2 in spermatozoa., Results: Of 112 men 45 (40.2%) were ALDH2*2 carriers. Among ALDH2*2 carriers, alcohol consumption was associated with significantly lower total sperm motility (median 20% [interquartile range 11%-42%] vs 43% [IQR 31%-57%], p=0.005) and progressive sperm motility (19% [IQR 11%-37%] vs 36% [IQR 25%-53%], p=0.008). Among alcohol consumers, ALDH2*2 carriers had significantly lower total sperm motility (20% [IQR 11%--42%] vs 41% [IQR 19%-57%], p=0.02), progressive sperm motility (19% [IQR 11%-37%] vs 37% [IQR 17%-50%], p=0.02) and total motile sperm count (28 million [M; IQR 9-79M] vs 71M [IQR 23-150M], p=0.05) compared to ALDH2*1/*1 individuals. Secondly, ALDH2 expression in human spermatozoa was significantly lower in ALDH2*2 carriers ( ALDH2*1/*1 vs ALDH2*1/*2 , p=0.01; ALDH2*1/*1 vs ALDH2*2/*2 , p <0.001)., Conclusions: Our findings suggest genotyping ALDH2, coupled with alcohol cessation counseling, may improve semen parameters among men.

Introduction: Following passage of the Affordable Care Act, Medicaid access was expanded in several states beginning in 2014. We sought to determine the oncologic implications by comparing outcomes between testicular germ cell tumor patients with Medicaid and those without insurance, and by assessing for changes in outcomes after 2014., Methods: A total of 18,506 men with seminomatous or nonseminomatous germ cell tumors were identified within the Surveillance, Epidemiology, and End Results database (2007-2016). Multivariable Cox proportional hazards, Fine and Gray competing-risks regression, propensity score matching, cumulative incidence plots and segmented Poisson regression models were used., Results: Compared to no insurance, Medicaid insurance was not associated with differences in all-cause mortality or cancer-specific mortality among seminoma patients (all-cause mortality: HR=1.24, p=0.87; cancer-specific mortality: HR=0.92, p=0.75) or nonseminoma patients (all-cause mortality: HR=1.13, p=0.33; cancer-specific mortality: HR=1.10, p=0.51). Among matched Medicaid and uninsured patients, there was again no difference in cancer-specific mortality for those with seminoma (p=0.81) or nonseminoma (p=0.23). There was a 99% increase in Medicaid enrollment in expansion states in the post-Affordable Care Act era. There was no difference in post-expansion all-cause mortality between expansion states and nonexpansion states for men with seminoma (p=0.42) or nonseminoma (p=0.53)., Conclusions: Medicaid enrollment increased in expansion states following the Affordable Care Act. However, there was no difference in survival between Medicaid patients and uninsured patients, or between patients in expansion states versus nonexpansion states, highlighting the need for population-level policy interventions to improve access and quality of care among testicular cancer patients with Medicaid.

Introduction: We sought to characterize public interest in elective urological procedures amid the COVID-19 pandemic, and specifically after the Centers for Medicare and Medicaid Services and the American Urological Association recommended cessation of all nonessential procedures., Methods: We extracted relative search volumes from Google Trends™ (January 2015 to May 2020) for keywords related to the 4 procedure categories of male infertility, erectile dysfunction, Peyronie's disease and vasectomy. The most popular keywords in each category were used to assess immediate (30 days preceding and following official recommendation from Centers for Medicare and Medicaid Services on March 18, 2020) and long-term (January 1, 2015 to March 18, 2020 vs March 19, 2020 to May 21, 2020) shifts in public interest. Lastly, we assessed geographical variations in public interest during the phase I reopening period from April 24 to May 31, 2020., Results: There was an immediate reduction in interest across all 4 categories following the Centers for Medicare and Medicaid Services recommendation. Long-term post-announcement relative search volume was lower than pre-announcement relative search volume in all categories as well, namely male infertility (54.33% vs 68.74%, p=0.02), erectile dysfunction (45.00% vs 76.74%, p <0.0001), Peyronie's disease (48.33% vs 77.95%, p <0.0001) and vasectomy (51.33% vs 66.73%, p=0.0005). During the phase I reopening period the relative search volume for vasectomy was higher in states that reopened early than in states that reopened late (60.29% vs 50.52%, p=0.029)., Conclusions: Public interest in elective urological procedures decreased following the onset of the COVID-19 pandemic and recommendations from the Centers for Medicare and Medicaid Services. Interest rebounded in May, seemingly driven by states that lifted their stay-at-home order earlier than others.